

Leopoldo S. Piegas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7670418/publications.pdf>

Version: 2024-02-01

51
papers

9,870
citations

230014

27
h-index

214428

50
g-index

52
all docs

52
docs citations

52
times ranked

11702
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
2	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021, 42, 2995-3007.	1.0	18
3	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 181-264.	0.3	45
4	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	1.0	15
5	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	2.9	11
6	Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial. <i>American Heart Journal</i> , 2019, 207, 40-48.	1.2	3
7	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
8	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
9	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	13.9	526
10	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	13.9	641
11	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	13.9	299
12	Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , 2016, 375, 2359-2368.	13.9	326
13	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016, 32, 311-318.	0.8	24
14	Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives. <i>Value in Health Regional Issues</i> , 2015, 8, 36-42.	0.5	10
15	Validation of the Killip-Kimball Classification and Late Mortality after Acute Myocardial Infarction. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 103, 107-17.	0.3	33
16	Prognostic Score for Acute Coronary Syndrome in a Private Tertiary Hospital. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 102, 226-36.	0.3	2
17	The Cost Implications of Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery at One Year. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1620-1625.	0.7	23
18	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013, 128, 237-243.	1.6	195

#	ARTICLE	IF	CITATIONS
19	Effects of Off-Pump and On-Pump Coronary-Artery Bypass Grafting at 1 Year. <i>New England Journal of Medicine</i> , 2013, 368, 1179-1188.	13.9	390
20	Myocardial protection with prophylactic oral metoprolol during coronary artery bypass grafting surgery: evaluation by troponin I. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2013, 28, 449-54.	0.2	5
21	Acute Coronary Syndrome Behavior: Results of a Brazilian Registry. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 100, 502-10.	0.3	28
22	Serum Adiponectin and Cardiometabolic Risk in Patients with Acute Coronary Syndromes. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 101, 399-409.	0.3	7
23	Mechanical Dyssynchrony is Similar in Different Patterns of Left Bundle-Branch Block. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 101, 449-56.	0.3	1
24	Off-Pump or On-Pump Coronary-Artery Bypass Grafting at 30 Days. <i>New England Journal of Medicine</i> , 2012, 366, 1489-1497.	13.9	620
25	Rationale and design of The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study: A large international randomized trial in cardiac surgery. <i>American Heart Journal</i> , 2012, 163, 1-6.	1.2	67
26	Intervenç�o coronariana percut�nea no Brasil: resultados do Sistema �nico de Sa�de. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 96, 317-324.	0.3	28
27	Initial Clinical Results Using Intracardiac Electrogram Monitoring to Detect and Alert Patients During Coronary Plaque Rupture and Ischemia. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1089-1098.	1.2	39
28	Fibrila�o atrial no p�s-operat�rio de cirurgia card�aca. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 93, 59-63.	0.3	17
29	Cirurgia de revasculariza�o mioc�rdica: resultados do Sistema �nico de Sa�de. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 93, 555-560.	0.3	37
30	The Guardian: an implantable system for chronic ambulatory monitoring of acute myocardial infarction. <i>Journal of Electrocardiology</i> , 2009, 42, 481-486.	0.4	13
31	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. <i>American Heart Journal</i> , 2009, 157, 763-770.	1.2	28
32	Magnitude and Prognosis Associated With Ventricular Arrhythmias in Patients Hospitalized With Acute Coronary Syndromes (from the GRACE Registry). <i>American Journal of Cardiology</i> , 2008, 102, 1577-1582.	0.7	31
33	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET) <i>TJ ETQq1 1 0.784314 rgBT / Overlook</i>	6.3	1,442
34	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2008, 118, 2038-2046.	1.6	98
35	Evolu�o cl�nica muito tardia de pacientes com infarto agudo do mioc�rdio submetidos a angioplastia prim�ria. <i>Arquivos Brasileiros De Cardiologia</i> , 2008, 90, 243-248.	0.3	0
36	Preval�ncia e fatores de risco na associa�o entre doen�a arterial coronariana e aneurisma de aorta. <i>Arquivos Brasileiros De Cardiologia</i> , 2007, 88, 40-44.	0.3	18

#	ARTICLE	IF	CITATIONS
37	Cardiomiopatia hipertrófica: importância dos eventos arritmicos em pacientes com risco de morte súbita. Arquivos Brasileiros De Cardiologia, 2006, 87, 649-657.	0.3	6
38	Registro de síndrome coronariana aguda em um centro de emergências em cardiologia. Arquivos Brasileiros De Cardiologia, 2006, 87, 597-602.	0.3	30
39	Implantable Cardioverter-Defibrillators: Expectations in the Brazilian Elderly. The American Journal of Geriatric Cardiology, 2006, 15, 357-360.	0.7	2
40	Influence of Age and Coronary Artery Disease on Homocysteine Levels in the Young Old Compared With the Old Old and the Oldest Old. The American Journal of Geriatric Cardiology, 2006, 15, 165-173.	0.7	4
41	Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2005, 293, 437.	3.8	581
42	Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the assessment of the safety of a new thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. American Heart Journal, 2004, 147, 993-998.	1.2	38
43	Risk factors for myocardial infarction in Brazil. American Heart Journal, 2003, 146, 331-338.	1.2	107
44	International variation in the use of evidence-based medicines for acute coronary syndromes. European Heart Journal, 2003, 24, 2133-2141.	1.0	35
45	Role of infarct size in explaining the higher mortality in older patients with acute myocardial infarction. American Journal of Cardiology, 2002, 90, 1370-1374.	0.7	6
46	The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. European Heart Journal, 2000, 21, 2033-2041.	1.0	248
47	Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction. Circulation, 2000, 102, 1014-1019.	1.6	688
48	The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina. American Journal of Cardiology, 1999, 84, 7-12.	0.7	51
49	Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet, The, 1999, 354, 716-722.	6.3	792
50	Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet, The, 1998, 352, 507-514.	6.3	340
51	Results of cardiopulmonary resuscitation in a cardiology hospital. Resuscitation, 1989, 18, 75-84.	1.3	18